Passiflora incarnata 30c homeopathic tablets
Available from pharmacies, supermarkets, and retail outlets
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Homeopathic passiflora incarnata
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Homeopathic passiflora incarnata on the MHRA register
Passiflora incarnata 30c homeopathic tablets
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 12 · Randomised trials: 3 · 2001–2026
Showing the 50 most relevant studies, sorted by most relevant.
Katarzyna Janda, Karolina Wojtkowska, Karolina Jakubczyk, et al.
Nutrients, 2020
Background: Stress is a natural response of the body, induced by factors of a physical (hunger, thirst, and infection) and/or psychological (perceived threat, anxiety, or concern) nature. Chronic, long-term stress may cause problems with sleep, concentration, and memory, as well as affective disorders. The passionflower (Passiflora incarnata) is a perennial plant with documented therapeutic properties. The literature data suggest that the passionflower itself, as well as its preparations, helps reduce stress and can therefore be helpful in the treatment of insomnia, anxiety, and depression. The objective of this systematic review was to evaluate Passiflora incarnata in terms of its neuropsychiatric effects. Methods: The scientific databases PubMed, ClinTrials.gov, and Embase were searched up to 22 October 2019. The search identified randomized clinical trials describing the effects of Passiflora incarnata in neuropsychiatric disorders. Results: The systematic review included nine clinical trials. The duration of the studies included in the analysis varied widely, from one day up to 30 days. Study participants were no less than 18 years old. In each of the papers, the effects of passionflower were measured by using a number of different tests and scales. The majority of studies reported reduced anxiety levels following the administration of Passiflora incarnata preparations, with the effect less evident in people with mild anxiety symptoms. No adverse effects, including memory loss or collapse of psychometric functions, were observed. Conclusion: Passiflora incarnata may be helpful in treating some symptoms in neuropsychiatric patients.
Abstract licence: CC BY 4.0
Mohammad Paracha, Faryal Fazal, S. A. Khan, et al.
medRxiv, 2025
Amalia Celsy Abregu Velasquez, M. Tsuji, Lidiana Dos Santos Cordeiro, et al.
Oral and Maxillofacial Surgery, 2024
Journal of Dietary Supplements, 2008
Janilson A Silva, M. Costa, Maria Dos Remédios da Silva Alves, et al.
International Archives of Medicine, 2017
M. Nematshahi, S. Mohammadi, Davood Soroosh, et al.
Indian Journal of Forensic Medicine & Toxicology, 2020
Sakshi S Madavi, Pankaj H. Chaudhary
International Journal of Pharmacognosy and Pharmaceutical Sciences, 2024
Mijin Kim, Hee-Sook Lim, Hae-Hyeog Lee, et al.
Journal of Menopausal Medicine, 2017
Balasubramanian Deepika, Koyeli Girigoswami
Traditional Medicine Research, 2026
Passiflora incarnata L., commonly known as passionflower, is traditionally cultivated as an ornamental plant but has demonstrated diverse therapeutic potential. Its pharmacological effects are attributed to bioactive compounds such as flavonoids and alkaloids, which influence multiple biological pathways. This review aims to summarise and critically analyse recent findings on the pharmacological properties of Passiflora incarnata L., focusing on its neuropsychiatric, antioxidant, antimicrobial, and anticancer activities. A targeted literature search was conducted in PubMed, Scopus, Web of Science, and Google Scholar for peer-reviewed publications between 2000 to 2025. Relevant articles were screened, and a more appropriate article related to the objective of the review was selected. Some classical papers are also cited as per the requirement of the topic. Passiflora incarnata L. showed multifunctional medicinal properties with various applications in neuropsychiatry, oxidative stress management, antimicrobial agent, and as an anticancer agent. The U.S. Food and Drug Administration categorizes passionflower extracts as “generally recognized as safe”. However, most evidence remains preclinical, with methodological variation limiting generalisation. Standardised formulation, robust clinical trials, and in-depth in vivo studies are essential to establish its therapeutic relevance and safety in modern medicine.
Abstract licence: CC BY
Meenu ., Ciya Sangwan, Muskan .
International Journal of Innovative Science and Research Technology, 2026
Passiflora incarnata Linn, commonly referred to as passionflower, is a traditional medicinal herb renowned for its soothing effects on the nervous system. It has long been utilized in the treatment of sleep disturbances, anxiety-related conditions, and inflammatory disorders. In recent years, growing scientific interest has positioned P. incarnata as a promising phytotherapeutic agent, particularly for neuropsychiatric and neuroprotective applications. The present review provides a comprehensive and integrative overview of P. incarnata, emphasizing its botanical characteristics, phytochemical composition, extraction methodologies, and pharmacological activities. Special attention is given to both conventional and advanced extraction techniques, highlighting how process parameters influence the recovery of flavonoids, alkaloids, and phenolic compounds responsible for the plant’s biological activity. The review summarizes current evidence supporting the sedative, anxiolytic, anticonvulsant, antidepressant, antioxidant, anti-inflammatory, antidiabetic, antimicrobial, and anticancer properties of P. incarnata. Mechanistic insights, particularly those involving modulation of the GABAergic system and oxidative stress pathways, are discussed to explain its neuropharmacological effects. Furthermore, the sustainable utilization of Passiflora biomass and the need for standardized extracts, optimized extraction protocols, and well-designed clinical studies are critically addressed. Overall, this review highlights P. incarnata as a valuable natural resource with significant therapeutic potential and underscores future research directions required for its successful translation into evidence-based herbal formulations. This review critically evaluates existing literature, provides comparative analysis of extraction techniques, and highlights key research gaps for future investigations.
Abstract licence: CC BY-NC
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.